Our Company

BioMed Valley Discoveries, Inc., is a for-profit, disease-related research and development organization, whose mission is to address unmet medical needs in areas that are considered too early or too unconventional for traditional biotech and pharmaceutical companies. Operating since 2007, BVD advances its mission with commercial capabilities and resources typically unavailable to academic institutions. As a member of the Stowers Group of Companies, BVD receives its funding principally from an endowment supporting the Stowers Institute for Medical Research, a non-profit 550-person basic biomedical research organization. One hundred percent of the profits from BVD accrue to the benefit of the Stowers Institute.


April 2, 2017: Dr. Ryan J. Sullivan, Harvard Medical School / MGH, Boston, MA presented at the AACR meeting in Washington, DC.

Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma.

Portfolio Highlights

  • 3

    Fast growing tumors exceed
    blood supply and leave an
    anaerobic center
    Newly discovered bacterial spores
    thrive in an anaerobic environment
    and target tumor's center
    C. novyi-NT consumes
    anaerobic cells of a tumor
  • 2

    Ligand binding
    activates extracellular
    Mutations in MAPK pathway result
    in excessive signaling
    BVD-523 inhibits
    aberrant signaling
    in the MAPK pathway
    Cell Proliferation,
    Growth, and Survival

William Osler

"To wrest from nature the secrets which have perplexed philosophers in all ages, to track to their sources the causes of disease, to correlate the vast stores of knowledge, that they may be quickly available for the prevention and cure of disease - these are our ambitions."

-William Osler, 1904

  • Oncolytic bacteria may provide significant benefit to patients with solid tumors.
    Read More
    Frequently Asked Questions
  • ERK inhibition may provide benefit to patient cancers that are dependent on MAPK pathway mutations. Read More